EDIT Looks 34.1% Overvalued on GF Value™ Amid Gene Editing Sector Volatility

On September 23, 2026, Editas Medicine Inc (NASDAQ: EDIT) shares declined nearly 5% following Anthropic's announcement of a novel CRISPR-like enzyme system disc

KabuDo's automated read: this looks like a positive signal for healthcare. Potentially affected tickers include EDIT (US) and 0IFK.L (GB).